Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.95 Analyst target: $9.80 Upside: 148.10%
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City, California.
See the full interactive analysis & chart →Informational only — not investment advice.